What medications are appropriate for treating hematuria in an adult based on the underlying cause?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 23, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Medications for Treating Hematuria in Adults

The treatment of hematuria in adults is fundamentally cause-directed rather than symptom-directed—there is no medication that "treats hematuria" itself; instead, you must identify and treat the underlying etiology. 1, 2

Core Principle: Diagnosis Before Treatment

Hematuria is a symptom, not a disease, and requires complete diagnostic evaluation before any therapeutic intervention. 1, 2 The appropriate medication depends entirely on the underlying cause identified through systematic work-up. 1, 3


Step 1: Confirm True Hematuria

  • Obtain microscopic urinalysis showing ≥3 RBCs per high-power field on a properly collected clean-catch specimen before initiating any work-up or treatment. 1, 2
  • Dipstick testing alone has only 65–99% specificity and can produce false positives from myoglobin, hemoglobin, or menstrual contamination. 1

Step 2: Identify the Underlying Cause

A. Urinary Tract Infection (UTI)

Medications:

  • Nitrofurantoin, fosfomycin, or trimethoprim-sulfamethoxazole for uncomplicated lower UTI (if local resistance <20%). 2
  • Fluoroquinolone or ceftriaxone for suspected pyelonephritis. 2

Critical caveat: Obtain urine culture before starting antibiotics. 1, 2 If hematuria persists 6 weeks after completing treatment, proceed with full urologic evaluation (cystoscopy + CT urography) because infection does not exclude concurrent malignancy. 1, 2


B. Urolithiasis (Kidney/Ureteral Stones)

Medications:

  • NSAIDs (e.g., ketorolac, ibuprofen) for acute pain control. 3
  • Alpha-blockers (e.g., tamsulosin 0.4 mg daily) to facilitate stone passage for distal ureteral stones <10 mm. 3
  • Antiemetics (e.g., ondansetron) if nausea/vomiting present. 3

Diagnostic confirmation: Unenhanced CT is gold standard for detecting stones. 1, 4


C. Benign Prostatic Hyperplasia (BPH)

Medications:

  • Alpha-blockers (e.g., tamsulosin, alfuzosin) to reduce bladder outlet obstruction. 1, 3
  • 5-alpha reductase inhibitors (e.g., finasteride, dutasteride) for prostate volume reduction in men with large prostates (>30 g). 3

Critical pitfall: Gross hematuria from BPH must be proven to be of prostatic origin through appropriate evaluation—never assume BPH is the cause without excluding malignancy via cystoscopy. 1


D. Glomerulonephritis (Glomerular Bleeding)

Indications for nephrology referral:

  • Dysmorphic RBCs >80% or red cell casts on microscopy. 1, 2
  • Protein-to-creatinine ratio >0.5 g/g (or >500 mg/24 hours). 1, 2
  • Elevated serum creatinine or declining renal function. 1, 2
  • Hypertension accompanying hematuria and proteinuria. 1, 2

Medications (nephrology-directed):

  • ACE inhibitors or ARBs for proteinuria reduction and blood pressure control in chronic kidney disease. 1
  • Corticosteroids for specific glomerulonephritides (e.g., IgA nephropathy, lupus nephritis) as determined by renal biopsy. 1
  • Immunosuppressants (e.g., cyclophosphamide, mycophenolate) for ANCA-associated vasculitis or severe lupus nephritis. 1

E. Interstitial Cystitis (IC) with Hematuria

Medications (after excluding malignancy via cystoscopy):

  • Pentosan polysulfate sodium (Elmiron) 100 mg three times daily as first-line oral therapy for IC without Hunner lesions. 5
  • Amitriptyline 25–75 mg at bedtime for pain modulation and bladder stabilization. 5
  • Intravesical dimethyl sulfoxide (DMSO) instillations for refractory cases. 5

Critical requirement: Cystoscopy is mandatory to identify Hunner lesions (which require fulguration/resection) and to exclude bladder cancer. 5


F. Anticoagulation-Related Hematuria

Management principle: Anticoagulants and antiplatelet agents do not cause hematuria—they may only unmask underlying pathology. 1, 2

Action required:

  • Do not discontinue anticoagulation without consulting the prescribing clinician. 1
  • Proceed with full urologic evaluation (cystoscopy + CT urography) regardless of anticoagulation status. 1, 2
  • If severe bleeding occurs, correct coagulopathy with appropriate reversal agents or blood products only after urologic consultation. 1

Step 3: Risk Stratification for Malignancy

High-risk features requiring urgent urologic evaluation (cystoscopy + CT urography):

  • Age ≥60 years (both men and women). 1, 2
  • Smoking history >30 pack-years. 1, 2
  • Any history of gross hematuria (even if self-limited). 1, 2
  • Occupational exposure to benzenes or aromatic amines. 1, 2
  • Irritative voiding symptoms without documented infection. 1, 2
  • Microscopic hematuria >25 RBCs/HPF. 1

Gross hematuria carries a 30–40% risk of malignancy and requires urgent urologic referral within 24–48 hours, even if bleeding is self-limited. 1, 2


Common Pitfalls to Avoid

  • Never attribute hematuria to anticoagulation alone—full evaluation is mandatory. 1, 2
  • Never ignore gross hematuria, even if transient—30–40% malignancy risk. 1, 2
  • Never skip cystoscopy in patients ≥40 years with confirmed microscopic hematuria—bladder cancer cannot be excluded by imaging alone. 1, 2
  • Never treat empirically with antibiotics without urine culture confirmation if infection is suspected. 1, 2
  • Never delay urologic evaluation while treating a UTI in patients >35 years—age alone is a sufficient risk factor for full work-up. 1, 2

Follow-Up Protocol (If Initial Work-Up Negative)

  • Repeat urinalysis at 6,12,24, and 36 months with blood pressure monitoring at each visit. 1, 2
  • After two consecutive negative annual urinalyses, further testing is unnecessary. 1
  • Immediate re-evaluation is warranted if gross hematuria develops, microscopic hematuria markedly increases, new urologic symptoms appear, or hypertension/proteinuria/glomerular bleeding emerges. 1, 2

References

Guideline

Hematuria Evaluation and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Management of Hematuria in the Outpatient Setting

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Assessment of hematuria.

The Medical clinics of North America, 2011

Research

Essentials of Computed Tomography Imaging of Hematuria.

Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2023

Guideline

Management of Interstitial Cystitis with Hematuria

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.